CIB4: A Calcium-Binding protein and Potential Drug Target (G130106)

Target Name: CIB4

NCBI ID: G130106

CIB4

CIB4: A Calcium-Binding protein and Potential Drug Target

CIB4 (Calcium and integrin-binding family member 4) is a protein that has been identified as a potential drug target and biomarker. It is a member of the integrin-binding family, which includes proteins that interact with integrins, a type of protein that plays a critical role in cell-cell adhesion. CIB4 is unique due to its ability to bind to both calcium ions and integrins, making it an attractive target for drug development.

CIB4's Structure and Function

CIB4 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and muscle. Its protein structure is characterized by a N-terminus that contains a unique calciotriodal domain, which is known for its ability to bind calcium ions. The calciotriodal domain is responsible for the protein's ability to bind to calcium ions and for its role in intracellular signaling.

In addition to its calciotriodal domain, CIB4 also has a unique C-terminus that is involved in its ability to interact with integrins. The C-terminus contains a conserved region that is known as the interaction domain, which is responsible for the protein's ability to interact with integrins.

CIB4's Role in Cell signaling

CIB4 is involved in various signaling pathways, including intracellular signaling, neurotransmission, and cell adhesion. One of the most well-studied functions of CIB4 is its role in intracellular signaling. CIB4 has been shown to play a role in the regulation of calcium ions, which are essential for various cellular processes.

In addition to its role in intracellular signaling, CIB4 has also been shown to play a critical role in cell adhesion. CIB4 has been shown to interact with integrins, which are proteins that play a critical role in the regulation of cell-cell adhesion. This interaction between CIB4 and integrins makes it an attractive target for drugs that are designed to modulate cell-cell adhesion.

CIB4's Potential as a Drug Target

CIB4's unique ability to bind to both calcium ions and integrins makes it an attractive target for drug development. Various studies have shown that modulating CIB4's activity can have a significant impact on cellular processes, including cell adhesion, neurotransmission, and intracellular signaling.

One of the most promising strategies for modulating CIB4's activity is the use of small molecules. Small molecules can be used to either activate or inhibit CIB4's activity, depending on its function in the cell. For example, small molecules can be used to modulate the activity of CIB4's calciotriodal domain, which is responsible for its ability to bind to calcium ions.

Another approach to modulating CIB4's activity is the use of antibodies. Antibodies can be used to specifically target CIB4 and either activate or inhibit its activity. This approach is particularly useful for studying the protein's function in the cell and for identifying potential drug targets.

Conclusion

CIB4 is a unique protein that has been identified as a potential drug target and biomarker. Its ability to bind to both calcium ions and integrins makes it an attractive target for drug development. Various studies have shown that modulating CIB4's activity can have a significant impact on cellular processes, including cell adhesion, neurotransmission, and intracellular signaling. For these reasons, CIB4 is a promising target for future drug development.

Protein Name: Calcium And Integrin Binding Family Member 4

The "CIB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CIB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets